Skip to main content
Hemostemix Inc. logo

Hemostemix Inc. — Investor Relations & Filings

Ticker · HEM ISIN · CA4236943060 LEI · 984500C65BB0B8159L77 TSXV Professional, scientific and technical activities
Open in API
Filings indexed 576 across all filing types
Latest filing 2023-01-19 Capital/Financing Update
Country CA Canada
Listing TSXV HEM

About Hemostemix Inc.

https://hemostemix.com/

Hemostemix Inc. is a clinical-stage biotechnology company specializing in regenerative medicine through the development and commercialization of autologous (patient's own) blood-derived stem cell therapies. The company's lead investigational product is ACP-01 (Angiogenic Precursor Cell treatment), a platform targeting ischemic conditions such as Critical Limb Ischemia (CLI), ischemic cardiomyopathy, and angina. ACP-01 is designed to address unmet medical needs, particularly in patients ineligible for standard revascularization procedures. Phase II clinical data re-examination for "no option" CLI indicated that ACP-01 administration was safe and associated with reduced ulcer size and decreased rates of amputation and death.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Capital/Financing Update Classification · 90% confidence The document is a press release announcing a Letter of Commitment and non-dilutive funding of $250,000 from the McGill University Health Centre Foundation to support a clinical trial by Hemostemix. It discusses the clinical trial, the company's background, and forward-looking statements about the trial and funding. There are no financial statements, regulatory filings, or detailed financial data presented. The document is an announcement of funding and partnership rather than a financial report, earnings release, or regulatory filing. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Capital/Financing Update since it is about a funding commitment and clinical trial support, not a financing transaction or capital structure change. The best fitting category is Capital/Financing Update (CAP) because it announces funding related to the company's clinical trial activities, which is a financing update though non-dilutive and philanthropic in nature. Confidence is high given the clear announcement of funding commitment and clinical trial support.
2023-01-19 English
News release - English.pdf
Regulatory Filings
2022-12-08 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release from Hemostemix Inc. thanking an individual for a testimonial interview and providing forward-looking statements about the company's product and clinical trials. It contains no financial data, no regulatory filings, no meeting materials, no voting results, no management or board changes, no earnings or interim reports, and no detailed investor presentations. The content is primarily promotional and informational about a testimonial and forward-looking statements, typical of a general regulatory announcement or news release. The document length is 6314 characters, which is relatively short and does not contain substantive financial or regulatory report content. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous announcements that do not fit other categories.
2022-11-30 English
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 100% confidence The document is a FORM 52-109FV2 Certification of Interim Filings Venture Issuer Basic Certificate. It is a certification letter by the Interim CFO regarding the review and fair presentation of the interim financial report and interim MD&A for the period ended September 30, 2022. The document does not contain actual financial data or substantive financial analysis but is an officer certification related to interim filings. According to the Certification Rule, such documents should be classified as Regulatory Filings (RNS) rather than as the interim report itself (IR). The document length is short (3021 characters) and is primarily a certification letter, not the report or announcement of a report publication. Therefore, the correct classification is Regulatory Filings (RNS).
2022-11-29 English
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 100% confidence The document is a FORM 52-109FV2 Certification of Interim Filings Venture Issuer Basic Certificate. It is a certification by the CEO regarding the review and fair presentation of the interim financial report and interim MD&A for the period ended September 30, 2022. The document does not contain actual financial data or substantive financial analysis but is an officer certification related to interim filings. According to the CERTIFICATION RULE, such documents should be classified as Regulatory Filings (RNS) rather than as the interim report itself (IR). The document length is short (3029 characters), and it is clearly a certification letter, not the interim report or MD&A itself.
2022-11-29 English
Interim MD&A - English.pdf
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Management’s Discussion and Analysis of the Results of Operations and Financial Condition' for the three and nine months ended September 30, 2022 and 2021. It contains detailed discussion of the company's operations, financial position, forward-looking statements, business overview, corporate updates, and financing activities. The presence of detailed financial discussion and analysis for an interim period, along with references to unaudited condensed consolidated interim financial statements, indicates this is a comprehensive interim or quarterly report. The document length is substantial (15,000 characters), and it contains substantive financial data and analysis, not merely an announcement or certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). 9M 2022
2022-11-29 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.